Trial Profile

Phase 1 trial of VRDN-001 in healthy volunteers

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Veligrotug (Primary)
Indications Graves ophthalmopathy
Focus Adverse reactions
Sponsors Viridian Therapeutics

Most Recent Events

08 Aug 2023 According to a Viridian Therapeutics media release, topline results from this study are expected in the fourth quarter of 2023
08 Aug 2023 According to a Viridian Therapeutics media release, status has been changed to active, no longer recruiting.
10 Jul 2023 According to a Viridian Therapeutics media release, this trial will initiate in the third quarter of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com